SAB Biotherapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 06/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $1.3 | $2.2 | $23.9 | — |
| Operating income | -$49.0 | -$42.9 | -$38.1 | -$28.9 | — |
| Net income | $13.3 | -$34.1 | -$42.2 | -$18.7 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$45.7 | -$34.6 | -$25.3 | -$25.6 | — |
Shares outstanding 91.0M · Free float 67.9%
Annual filing data through FY ended December 31, 2025; float as of October 14, 2026.
SAB Biotherapeutics Posts $22.3 Million Loss as SAFEGUARD Costs Rise